Search results

2384 results

Sorted by Relevance . Sort by Date

  1. Gambling

    Proposed [GID-QS10099] Expected publication date: TBC

  2. Gout

    Proposed [GID-QS10100] Expected publication date: TBC

  3. Pernicious anaemia

    Proposed [GID-QS10130] Expected publication date: TBC

  4. Tinnitus

    Proposed [GID-QS10091] Expected publication date: TBC

  5. Diverticular disease

    Proposed [GID-QS10086] Expected publication date: TBC

  6. Acne

    Proposed [GID-QS10036] Expected publication date: TBC

  7. Adrenal dysfunction

    Proposed [GID-QS10038] Expected publication date: TBC

  8. Thyroid disease

    Proposed [GID-QS10088] Expected publication date: TBC

  9. Perioperative care

    In development [GID-QS10094] Expected publication date: TBC

  10. Supporting adult carers

    In development [GID-QS10128] Expected publication date: 19 March 2021

  11. Renin-angiotensin system drugs: dual therapy (KTT2)

    The key therapeutic topic renin-angiotensin system drugs: dual therapy has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .

  12. Minocycline (KTT11)

    The key therapeutic topic minocycline has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .

  13. Laxatives (KTT1)

    The key therapeutic topic laxatives has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .

  14. First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)

    The key therapeutic topic first-choice antidepressant use in adults with depression or generalised anxiety disorder has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .

  15. Antimicrobial stewardship: prescribing antibiotics (KTT9)

    This document summarises the evidence base on antimicrobial stewardship: prescribing antibiotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  16. Antipsychotics in people living with dementia (KTT7)

    This document summarises the evidence base on antipsychotics in people living with dementia . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  17. Hypnotics (KTT6)

    This document summarises the evidence base on hypnotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  18. Asthma: medicines safety priorities (KTT5)

    This document summarises the evidence base on asthma: medicines safety priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  19. Lipid-modifying drugs (KTT3)

    This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  20. Shared decision making (KTT23)

    This document summarises the evidence base on shared decision making . It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance .

  21. Chemotherapy dose standardisation (KTT22)

    This document summarises the evidence base on chemotherapy dose standardisation . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .